Funding Opportunities Tracking
FOA No. | Title | Org | Release/Open Dates | Exp. Date | Activity Code(s) | No. Awards | Amount | Comments |
---|---|---|---|---|---|---|---|---|
RFA-DA-20-025 | Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research (U18 - Clinical Trial Not Allowed) | NIDA | Release Date: 11/14/2019 Open Date: 01/13/2020 | 02/14/2020 | U18 | Estimate of 50 awards | $150,000 directs/year | |
FOA-ETA-20-01 | The Support to Communities: Fostering Opioid Recovery Through Workforce Development | NIDA | Release Date: 10/31/2019 Open Date: | 01/10/2020 | Up to $5,000,000 | |||
PAR-20-035 | Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional) | NIDA, NCI, NIAAA | Release Date: 10/18/2019 Open Date: 02/17/2020 | 11/08/2022 | R61/R33 | Contingent upon appropriations | Up to $300,000 | |
NOT-HS-20-001 | Notice of Intent to Publish Funding Opportunity Announcement to Improve the Management of Opioids and Opioid Use Disorder in Older Adults | AHRQ | Release Date: 10/25/2019 Open Date: | |||||
BJA-2020-17754 | BJA FY 20 Harold Rogers Prescription Drug Monitoring Program (PDMP) | Department of Justice Bureau of Justice Assistance | Release Date: 03/06/2020 Open Date: | 03/05/2020 | 14 | $2,000,000 | ||
PAR-20-118 | National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional) | NIH | Release Date: 02/25/2020 Open Date: 06/27/2020 | 03/26/2022 | U01 | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. | Application budgets are not limited but need to reflect the actual needs of the proposed project. | |
PAR-20-119 | National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Substance Use Disorders, or Alcohol Use Disorder (U19 Clinical Trial Optional) | NIH | Release Date: 02/25/2020 Open Date: 06/27/2020 | 03/26/2022 | U19 | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. | Application budgets are not limited but need to reflect the actual needs of the proposed project. | |
BJA-2020-17106 | BJA FY 20 Improving Reentry for Adults with Substance Use Disorders Program | Department of Justice Bureau of Justice Assistance | Release Date: 02/26/2020 Open Date: | 04/27/2020 | 14 | $900,000 ceiling | ||
BJA-2020-17023 | BJA FY 20 Comprehensive Opioid, Stimulant, and Substance Abuse Site-based Program (COSSAP) | Department of Justice Bureau of Justice Assistance | Release Date: 02/21/2020 Open Date: 02/21/2020 | 05/21/2020 | 120 | $6,000,000 | ||
TI-20-010 | State Pilot Grant Program for Treatment for Pregnant and Postpartum Women | SAMHSA | Release Date: 02/19/2020 Open Date: | 04/20/2020 | 5 | Up to $900,000 | ||
TI-20-011 | 2020 Tribal Opioid Response grants | SAMHSA | Release Date: 03/03/2020 Open Date: 03/03/2020 | 05/04/2020 | 200 | $1,800,000 | ||
TI-20-007 | Services Grant Program for Residential Treatment for Pregnant and Postpartum Women | SAMHSA | Release Date: 01/30/2020 Open Date: 01/30/2020 | 03/30/2020 | 3 | $1,800,000 | ||
PAR-20-092 | Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional) | NIDA | Release Date: 01/24/2020 Open Date: 01/24/2020 | 09/02/2022 | UG3/UH3 | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. | $3M/year in directs | |
HRSA-20-014 | Opioid-Impacted Family Support Program | Release Date: Open Date: | 19 | |||||
TI-20-006 | SAMHSA | Release Date: 01/17/2020 Open Date: 01/17/2020 | 03/17/2020 | 2 | $850,000/year | |||
RFA-FD-20-031 | Incorporating cost effectiveness & societal outcomes into FDA opioids model (U01) Clinical Trials Not Allowed | FDA | Release Date: 03/13/2020 Open Date: 03/16/2020 | 05/19/2020 | U01 | The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support. | 1,000,000 | |
RFA-DA-21-001 | Reducing Stigma Related to Drug Use in Human Service Settings (R34 Clinical Trial Required) Department of Health and Human Services National Institutes of Health | DHHS/NIH | Release Date: 04/09/2020 Open Date: | 08/11/2020 | R34 | 2 | $450,000 | |
NOT-DA-20-044 | Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional) | DHHS/NIH | Release Date: 04/06/2020 Open Date: 05/01/2020 | 07/13/2020 | $700,000 | |||
CDC-RFA-CE20-2002 | Drug-Free Communities (DFC) Support Program-New | CDC | Release Date: 02/18/2020 Open Date: | 06/08/2020 | 200 | $125,000 | ||
I-20-013 | Treatment, Recovery, and Workforce Support Grant | SAMHSA | Release Date: 03/31/2020 Open Date: | 06/01/2020 | 8 | $500,000 | ||
NOT-MD-20-019 | Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities | NIMHD, NIA, NIMH | Release Date: 04/10/2020 Open Date: 05/01/2020 | 05/01/2021 | P20 | 125,000 | ||
PA-20-208 | Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional) | NIDA | Release Date: 05/16/2020 Open Date: 05/16/2020 | 05/23/2023 | R36 | Contingent upon meritorious applications | No more than $50,000/year | |
PAR-20-182 | Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed) | NIDA | Release Date: 05/04/2020 Open Date: 09/30/2020 | 10/31/2020 | R01 | 1-3 | Less than $1M/year for upt ot 5 years | |
CDC-RFA-CE20-2002 | Drug-Free Communities (DFC) Support Program-New Department of Health and Human Services Centers for Disease Control - NCIPC | CDC | Release Date: 02/18/2020 Open Date: 02/18/2020 | 06/08/2020 | 200 | $125,000 | ||
PAR-20-224 | Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) | Release Date: 06/01/2020 Open Date: 07/13/2020 | 08/16/2020 | DP2 | $375,000 | |||
PAR-20-225 | Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) | Release Date: 06/01/2020 Open Date: 09/19/2020 | 10/20/2022 | DP1 | Contingent upon appropriations | $300,000 | ||
PAR-20-241 | Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed) | NIDA | Release Date: 06/24/2020 Open Date: 09/30/2020 | 10/31/2020 | R01 | 1-3 | $1M | |
RFA-DA-21-024 | PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional) | NIDA/NIAID | Release Date: 06/29/2020 Open Date: 10/12/2020 | 11/13/2020 | R01 | 2-3 | $2.5M over 5 years | |
PAR-20-249 | NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) | NIDA | Release Date: 07/01/2020 Open Date: 02/01/2021 | 11/16/2023 | K12 | Contingent upon NIH appropriations | $500K/year | |
Systems for Action: Supplemental Research on COVID-19 Response and Recovery | Robert Wood Johnson Foundation | Release Date: Open Date: | 08/05/2020 | Foundation | 5 | Up to $100K/year | ||
PAR-20-237 | Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) | Release Date: 06/17/2020 Open Date: 07/28/2020 | 12/02/2020 | R01 | Contingent upon NIH appropriations | $500,000/year | ||
RFA-DA-21-024 | PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional) | NIDA, NIAID | Release Date: 06/29/2020 Open Date: 10/12/2020 | 11/13/2020 | R01 | 2-3 | Not limited | |
PAR-20-279 | Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional) | NIDA/NIAAA | Release Date: 07/27/2020 Open Date: 11/15/2020 | 08/11/2023 | UG3/UH3 | Contingent upon meritorious applications | $500K per year | |
PAR-20-267 | NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) | NIDA | Release Date: 07/17/2020 Open Date: 08/25/2020 | 11/18/2022 | P30 | Contingent upon meritorious applications | Not limited | |
PAR-20-249 | NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) | NIDA | Release Date: 07/01/2020 Open Date: 02/01/2021 | 11/16/2023 | K12 | Contingent upon meritorious applications | $500K per year | |
HRSA-21-088 | Rural Communities Opioid Response Program – Implementation | HRSA | Release Date: 09/04/2020 Open Date: | 78 | 78M total program | |||
SP-19-006 | Drug-Free Communities (DFC) Support Program-Competing Continuation | DFC | Release Date: Open Date: | |||||
SP-19-005 | Drug-Free Communities (DFC) Support Program-New | DFC | Release Date: Open Date: | |||||
RFA-DA-20-019 | Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed) | NIDA | Release Date: 05/30/2019 Open Date: 09/17/2019 | R61/R33 | 5 | Up to $300K | ||
PA-FPR-19-001 | FORECASTED: Availability of funds for Title X Family Planning– Innovations in Family Planning Clinical Service Delivery and Studies to Address Opportunities and Barriers for Linking Family Planning Services and Substance Use Disorder Screening and Treatment | DHHS/OASH | Release Date: Open Date: | 10 | $400K | |||
HHS-2019-ACF-ACYF-CU-1568 | Regional Partnership Grants to Improve Well-Being and Permanency Outcomes for Children and Families Affected by Opioids and Other Substance Abuse | DHHS | Release Date: Open Date: | 7 | Up to $2.65M | |||
BJA-2019-15111 | BJA FY 19 Comprehensive Opioid Abuse Site-based Program | DOJ | Release Date: 04/05/2019 Open Date: | 150 | Up to $5M | |||
BAA-DAIT-75N93019R00009 | Development of Vaccines for the Treatment of Opioid Use Disorder | NIAID | Release Date: 03/05/2019 Open Date: | $2-3M/year | ||||
NOT-DA-19-048 | Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction | Release Date: Open Date: | ||||||
NOT-DA-19-041 | Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research | Release Date: Open Date: | ||||||
NOT-DA-19-38 | Notice of Special Interest (NOSI): Gene-Environment Interplay in Substance Use Disorders (R01, R21) | Release Date: Open Date: | ||||||
NOT-DA-19-037 | Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03) | Release Date: Open Date: | ||||||
NOT-DA-19-035 | Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) | NIDA | Release Date: Open Date: | |||||
PAR-19-282 | Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | NIDA | Release Date: 05/15/2019 Open Date: 09/10/2019 | 05/08/2023 | R61/R33 | Contingent | See announcement | |
PAR-19-207 | Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed) | NIAAA/NIDA | Release Date: 03/04/2019 Open Date: 04/25/2019 | 09/08/2022 | R25 | not limited | Not limited | |
PAR-19-207 | Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed) | NIAAA/NIDA | Release Date: 03/04/2019 Open Date: 04/25/2019 | 09/08/2022 | R01 | Not limited | ||
PAR-19-327 | Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional) | NIDA | Release Date: 08/01/2019 Open Date: 07/26/2019 | 09/02/2022 | U01 | three to four | Up to $5M/year | |
PAR-19-318 | Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01Clinical Trial Optional) | NIDA | Release Date: 07/26/2019 Open Date: 08/26/2019 | 09/02/2022 | R01 | Contingent | Up to $3M/year | |
PA-19-201 | Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional) | NIH | Release Date: 02/28/2019 Open Date: 05/16/2019 | 07/08/2022 | R21 | $275K/2 years | ||
PA-19-200 | Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional) | NIH | Release Date: 02/28/2019 Open Date: 05/05/2019 | 07/08/2022 | R01 | Not limited | ||
PA-18-946 | Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/16/2018 | 01/08/2022 | R21 | $275K for 2 years | ||
PA-18-945 | Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/05/2019 | 01/08/2022 | R01 | Not limited | ||
PA-18-944 | Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/05/2018 | 01/08/2022 | R01 | Not limited | ||
PA-18-943 | Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/16/2018 | 01/08/2022 | R21 | $275K for 2 years | ||
NOT-DA-19-066 | Notice of Special Interest (NOSI): Epidemiology of Drug Abuse | NIDA | Release Date: 08/29/2019 Open Date: 10/05/2019 | 01/08/2022 | ||||
PAR-19-278 | Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | NIDA | Release Date: 05/08/2019 Open Date: 05/24/2019 | 12/18/2021 | R21/R33 | R21 - Not to exceed $125K/year. R33-Not to exceed $250K | ||
PAR-19-100 | Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional) | NCATS | Release Date: 12/12/2018 Open Date: 02/08/2019 | 11/10/2021 | R21 | Not to exceed $200K | ||
PAR-19-099 | Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award, (U01 Clinical Trial Optional) | NCATS | Release Date: 12/12/2018 Open Date: 02/08/2019 | 11/10/2021 | U01 | Clinical not to exceed $750K. Non-clinical not to exceed $400K | ||
PAR-19-064 | Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) | NIDA | Release Date: 11/09/2019 Open Date: 01/08/2019 | 11/09/2021 | R21 | $275K for 2 years | ||
PAR-19-223 | Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) | NIDA | Release Date: 03/18/2019 Open Date: 09/21/2019 | 10/20/2021 | $up to 300K for up to 5 years | |||
RFA-DA-19-020 | HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 - Clinical Trial Optional) | NIDA | Release Date: 12/10/2018 Open Date: 01/10/2019 | 09/09/2021 | R41/R42 | 3 to 10 | Total $3M FY2019 | |
RFA-DA-19-019 | HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional) | NIDA | Release Date: 12/10/2018 Open Date: 12/10/2018 | 09/09/2021 | R43/R44 | 10 to 30 | Total $7M FY2019 | |
RFA-NS-19-018 | HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional) | NINDS | Release Date: 12/10/2018 Open Date: 12/10/2018 | 02/23/2021 | UH3 | 3 to 4 | Total $3M | |
RFA-NS-19-017 | HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional) | NINDS | Release Date: 12/10/2018 Open Date: 12/10/2018 | 02/23/2021 | U44 | 4 to 8 | Not to exceed $1M/year in Phase 1 | |
RFA-NS-19-016 | HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional) | NINDS | Release Date: 12/10/2018 Open Date: 12/09/2018 | 02/23/2021 | UG3/UH3 | 3 to 6 | Total $4M | |
RFA-EB-18-003 | HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed) | NIBIB | Release Date: 12/10/2018 Open Date: 01/08/2019 | 02/23/2021 | U18 | 5 to 10 | Not to exceed $500K | |
PA-18-591 | Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) | NIH | Release Date: 01/25/2018 Open Date: 01/25/2018 | 01/26/2021 | ||||
PAR-18-747 | Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional) | NIMHD | Release Date: 04/10/2018 Open Date: 05/15/2018 | 11/14/2020 | R01 | Not limited | ||
PAR-18-745 | Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional) | NIMHD | Release Date: 04/10/2018 Open Date: 05/15/2018 | 11/14/2020 | R21 | $275K for 2 years | ||
PAS-18-625 | Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional) | NIDA | Release Date: 02/02/2018 Open Date: 05/16/2018 | 09/08/2020 | R21 | 3 to 5 | Total $2M for FY2019 | |
PAS-18-625 | Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional) | NIDA | Release Date: 02/02/2018 Open Date: 05/16/2018 | 09/08/2020 | R21 | 3 to 5 | $275K total project | |
PAR-18-746 | NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) | NIDA | Release Date: 04/06/2018 Open Date: 05/11/2018 | 08/29/2020 | K12 | $500K Direct costs/year | ||
RFA-DA-18-022 | Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01 Clinical Trial Optional) | NIDA | Release Date: 03/14/2018 Open Date: 07/22/2018 | 08/22/2020 | R01 | 3 to 4 | ||
RFA-DA-18-020 | NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional) | NIDA | Release Date: 12/06/2018 Open Date: 06/25/2019 | 07/26/2020 | UG3/UH3 | Up to 2/year | Total $2M FY2019 | |
PA-18-079 | Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional) | NIDA/NIA | Release Date: 11/03/2017 Open Date: 01/17/2018 | 05/08/2020 | R21 | $275K for 2 years | ||
PA-18-061 | Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional) | NIDA/NIA | Release Date: 11/03/2017 Open Date: 01/06/2018 | 05/08/2020 | R01 | Not limited | ||
PA-17-157 | Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21) | NIDA | Release Date: 02/08/2017 Open Date: 05/16/2017 | 05/08/2020 | R21 | $275K for 2 years | ||
PA-17-155 | Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01) | NIDA | Release Date: 02/08/2017 Open Date: 05/05/2017 | 05/08/2020 | R01 | Not limited | ||
PA-17-134 | Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03) | NIAAA | Release Date: 01/25/2017 Open Date: 05/16/2017 | 05/08/2020 | R03 | $50K/year | ||
PA-17-132 | Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21) | NIAAA | Release Date: 01/25/2017 Open Date: 05/16/2017 | 05/08/2020 | R21 | $275K for 2 years | ||
HRSA-20-031 | Rural Communities Opiod Response Program - Implementation | HRSA | Release Date: 05/13/2019 Open Date: | 05/26/2020 | 79 | $79M program | ||
RFA-NS-18-046 | Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional) | NINDS | Release Date: 09/19/2018 Open Date: 10/27/2018 | 03/13/2020 | R61/R33 | 8 to 10 | Not limited | |
RFA-NS-18-041 | Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional) | NINDS | Release Date: 08/02/2018 Open Date: 10/27/2018 | 03/13/2020 | R61/R33 | 8 to 10 | Not limited | |
RFA-DA-19-002 | Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional) | NIDA | Release Date: 12/14/2017 Open Date: 01/25/2018 | 02/23/2020 | UG3/UH3 | 3 to 4 | Total $10M/Fiscal year | |
PA-18-078 | Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional) | NIDA | Release Date: 11/03/2017 Open Date: 01/17/2018 | 01/08/2020 | R21 | $275K for 2 years | ||
PA-17-120 | Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01) | NIDA | Release Date: 01/10/2017 Open Date: 01/10/2017 | 01/08/2020 | R01 | Not limited | ||
HRSA-20-106 | Rural Communities Opioid Response Program – Neonatal Abstinence Syndrome (RCORP-NAS) | Department of Health and Human Services Health Resources and Services Administration | Release Date: 02/06/2020 Open Date: 02/06/2020 | 04/14/2020 | 30 | Estimated Total Program Funding: | ||
FOR-FD-20-008 | FOR-FD-20-008 | Food and Drug Administration | Release Date: Open Date: 03/06/2020 | Forecasted | ||||
HHS-2020-IHS-COIPP-0001 | Community Opioid Intervention Pilot Project | Department of Health and Human Services | Release Date: 02/14/2020 Open Date: | Forecasted | ||||
HRSA-21-091 | Rural Communities Opioid Response Program – Psychostimulant Support | HRSA | Release Date: 01/06/2021 Open Date: | 15 | $7.5M Total program | Forecasted | ||
Strengthening Access to Care for Opioid Use Disorder Patients During the COVID-19 National Public Health Emergency: Recovery Support Services | FORE | Release Date: 05/22/2020 Open Date: 05/22/2020 | 07/31/2020 | Foundation | Contingent upon NIH appropriations | $25K-$75K | https://forefdn.org/wp-content/uploads/2020/05/COVID19_RFP_FINAL_5-22-2020.pdf | |
NOT-TR-20-025 | NCATS Announces Plans to Publish the ASPIRE 2020 Reduction-to-Practice Challenge Prize Competition | NCATS | Release Date: 08/26/2020 Open Date: | In this Reduction-to-Practice Challenge, the second phase of the initiative, NCATS aims to build upon the designs from the Design Challenges and reward the development of a working prototype of a comprehensive integrated platform, culminating in the development of better, more effective and non-addictive analgesics. It is anticipated that this Challenge would require large, multi-expert teams. These teams may be assembled from the innovators from the 2018 Design Challenge areas and others who did not participate in the 2018 Design Challenges. This Notice alerts the scientific community that NCATS intends to hold a three-stage prize open competition for the NCATS ASPIRE Reduction-to-Practice Challenge, the stages are 1) planning, 2) prototype development and milestones delivery, and 3) prototype delivery and validation and testing. It is anticipated that the announcement will be published in September 2020, with the submission window for Stage 1 planning solutions from late November through the end of February 2021. | ||||
RFA-HL-20-031 | HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed) Department of Health and Human Services | NIH | Release Date: 01/24/2020 Open Date: 01/24/2020 | 03/24/2020 | R61/R33 | NHLBI intends to commit total costs of up to $7,000,000 in FY2020-2021 to fund up to 10Phase I (R61) awards. NHLBI intends to commit total costs of up to $3,000,000 per year in FY2022-2024 to fund up to 5 Phase II (R33) awards. | ||
NOT-DA-20-071 | Rural Communities Opioid Response Program – Psychostimulant Support | HRSA | Release Date: 11/01/2020 Open Date: | 3 | Notice The National Institute on Health (NIH) intends to publish two Funding Opportunity Announcements (FOA) to solicit applications to build a network of researchers to develop sustainable evidence-based interventions to effectively treat non-cancer chronic pain (CP) and opioid use disorder (OUD). This network will be part of the of the NIH’s Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. | |||
PAR-20-221 | NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) | NIDA | Release Date: 06/01/2020 Open Date: 07/13/2020 | 08/16/2022 | DP1 | 2-3 awards/year | $700,000 | Reissue of RFA-DA-18-019 |
FOA No. | Title | Org | Release/Open Dates | Exp. Date | Activity Code(s) | No. Awards | Amount | Comments |